Secular trend analysis of antibiotic consumption in China's hospitals 2011-2018, a retrospective analysis of sales data

Haishaerjiang Wushouer

Chinese Academy of Engineering

Yue Zhou

Peking University Health Science Centre

Xi Zhang

Peking University Health Science Centre

Mengyuan Fu

Peking University Health Science Centre

Daiming Fan

Air Force Military Medical University

Luwen Shi

Peking University Health Science Centre

Xiaodong Guan (✉ guanxiaodong@pku.edu.cn)

Peking University Health Science Centre <https://orcid.org/0000-0002-1290-3827>

Research

Keywords: trend, antibiotic, sales, hospitals, China

Posted Date: February 19th, 2020

DOI: <https://doi.org/10.21203/rs.2.17021/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: This study was aimed to explore the secular trends of antibiotic sales over an 8-year period.

Methods: We retrospectively analysed aggregated monthly surveillance data on antibiotic sales to 586 hospitals from 28 provinces in China from January 2011 to December 2018. Information including generic name, sales amount, dosage form, strength, the route of administration, and geographical data were collected. Population weighted antibiotic sales were expressed in DDD per 1,000 inhabitants per day (DID). WHO's 'Access, Watch, Reserve' categorization was also adopted to analyse antibiotic sales.

Results: Between 2011 and 2018, total antibiotic sales in China's hospitals increased by 39.6% (from 4.8 DID in 2010 to 6.7 DID in 2018). Antibiotic sales were stable or had moderately decreased in 13 provinces, while in the other 15 provinces they had substantially increased. Cephalosporins were the most consumed antibiotics, accounting for 26.9% of the total antibiotic sales (1.8 DID/6.7 DID). In 2018, antibiotics in the Access category comprised 19.4% of the total sales (1.3 DID/6.7 DID), where antibiotics in the Watch category comprised the largest proportion of 71.6% (4.8 DID/6.7 DID). Population-weighted antibiotic sales were greater in secondary hospitals than in tertiary hospitals (7.3 DID vs 6.6 DID). The antibiotics sales of oral form were almost two times the sales of parenteral forms in secondary hospitals, whereas in tertiary hospitals the amounts were about the same.

Conclusions: Although efforts were made towards restricting antibiotics in the past decade by the Chinese government, antibiotic sales demonstrated an upward trend during the study period. More efforts are needed to explore whether the antibiotics are prudently used.

Background

Selection pressure from antibiotic use is considered to be one of the most important drivers of antimicrobial resistance (AMR), which is a growing public health threat of broad concern to the world [1]. At the G20 Hangzhou Summit in 2016, AMR was one of the main topics and was included in the final communiqué. At the 71st UN General Assembly, AMR was the fourth health-related topic that was discussed in UN General Assembly in history. It has been estimated that more than two million lives would be at risk, and up to 3.5 billion US dollars will be spent annually on average due to AMR in Europe, North America and Australia by 2050 if no action is taken [2]. According to the theory of choice, there is an expected net benefit of antibiotics use to the individual. Therefore protecting the efficacy of antibacterial agents and confining AMR should be a common goal of every country. China is estimated to be the second-largest consumer of antibiotics in the world [4]. This gives China an important role in the process of constraining the use and misuse of antibiotics.

To address this issue, China has taken many measures to strengthen antimicrobials management such as the designation of antibiotics as prescription drugs in 2003, and the introduction of guidance for clinical use of antibiotics in 2004 [5, 6]. National surveillance networks for both antibiotic use and resistance were established in 2005, along with the introduction of a national formulary in 2008 [7, 8]. However, due to the inefficient implementation and the absence of supervision and inspection, these policies and strategies did not fully achieve the expected results [4]. The overuse of antimicrobials has remained a serious public health challenge. Since the 2009 health system reform, the Chinese government has been committed to tackling the inappropriate use of antibiotics by enhancing antimicrobial stewardship. World Health Organization (WHO) called for urgent and concerted action to slow down the emergence and spread of drug resistance, with the slogan of "no action today, no cure tomorrow" in 2011. Echoing the global governance endeavors of the WHO, the National Health and Family Planning Commission (NHFPC) launched a three-year Special Antimicrobial Stewardship Campaign (SAC) nationwide to strengthen the management of clinical use antimicrobials in healthcare settings [9]. The SAC was legislated then as a ministerial decree in 2012 [10]. In addition, structured antimicrobial formulary restriction management has been established, which categorized antimicrobials into three classes (non-restricted, restricted and highly-restricted), with different prescription privileges to different levels of physicians. In 2016, a national action plan to confine AMR was released responding to WHO's call for the "Global Action Plan on Antimicrobial Resistance" [11]. Moreover, to respond to the emerging carbapenem-resistant bacteria, the NHFPC made specific and more restrictive requirements for the clinical use of carbapenems and tigecycline in 2018 [12].

Studies have centered around short-term trends of antibiotic sales in China [13, 14]. However, the long-term change in antibiotic sales, especially after nearly a decade since health system reform, was yet to be explored. Hence, this study was designed to explore the secular trends of antibiotic sales over an 8-year period.

Methods

Study design

We retrospectively analysed aggregated monthly surveillance data on antibiotic sales to 586 hospitals from 28 provinces in China from January 2011 to December 2018 (Table 1).

Table 1 Distribution of sample hospitals

Region ^a	Tertiary ^b	Secondary ^c
Eastern	256/982 (26.1)	73/1991 (3.7)
Middle	132/602 (21.9)	36/2132 (1.4)
Western	64/484 (13.2)	25/1763 (1.7)
Total	452/2068 (21.9)	134/5886 (2.3)

^a: Classification of the regions was obtained from the China Health Statistics Yearbook. Eastern region: Beijing, Tianjin, Hebei, Liaoning, Shanghai, Jiangsu, Zhejiang, Shandong, and Guangdong; Middle region: Shanxi, Jilin, Heilongjiang, Anhui, Jiangxi, Henan, Hubei, and Hunan; Western region: Inner Mongolia, Chongqing, Guangxi, Sichuan, Guizhou, Yunnan, Shaanxi, Gansu, Ningxia, and Xinjiang.

^b: Percentage in parenthesis was calculated by dividing the number of sampled tertiary hospitals by the total number of tertiary hospitals in the region.

^c: Percentage in parenthesis was calculated by dividing the number of sampled secondary hospitals by the total number of secondary hospitals in the region.

Data source

All the data was obtained from China Medicine Economic Information (CMEI), an observational database containing information of drug sales records (i.e. acquisition data, not the usage data) in medical institutions from 28 provinces (out of 34) across the country (Qinghai, Tibet, Hainan, Hongkong, Macau, and Taiwan excluded). The database covers more than 1,000 city-level public hospitals, including outpatient and inpatient, across mainland China. The sales of participating hospitals, which were all public hospitals, account for approximately 40% of total drug sales at city level public hospitals in China. Hospitals were sampled hierarchically based on geographical and socio-economic factors[14]. Hospitals were selected on the basis that they each had full records of antibiotic sales during the study period of 8 years. Based on this criterion, the selected 452 tertiary hospitals accounted for 21.9% of the total tertiary hospitals and the selected 134 secondary hospitals accounted for 2.3% of the total secondary hospitals in the study regions.

Data collection and management

We extracted monthly antibiotic sales records data from the CMEI electronic database. Information including the generic name, sales amount, dosage form, strength, the route of administration, and geographical data were collected. Hospital names were concealed to protect confidentiality. Sales data were categorized according to Anatomical Therapeutic and Chemical (ATC) classification J01 (i.e. antibacterial for systemic use) expressed in defined daily dose (DDD) as a measurement unit, following the recommendation of the WHO Collaborating Center for Drug Statistic Methodology [15]. The DDD of the drugs which could not be coded in the ATC system was calculated as the recommended daily amount for each study medication based on the dosage regimen recommended in the manufacturers' instructions, as approved by China Food and Drug Administration. A total of 186 unique chemical substance names were identified in single or combination antibiotics. These antibiotics were aggregated into 32 ATC-4 classes and then into 9 ATC-3 groups. Data were managed and analysed in Microsoft Excel 2013 and STATA 14.0 (StataCorp LLC, Texas, USA).

Data analysis

To make the antibiotic sales data consistent with the international standards, the data were converted into DDD per 1,000 inhabitants per day (DID) at the level of the active substance. Based on the following two assumptions, equation1 was adopted to calculate the weighted population as a proxy for the population our sample hospitals had covered. The first assumption is that there was no significant difference in the distribution of the sample hospitals across the provinces; second, there was no significant difference in the distribution of the population which was covered by the sample hospitals across the provinces. To avoid bias in calculating inhabitants, the inhabitants' coverage were calculated together for outpatient and inpatient, instead of separate calculation as we did before [14]. The inhabitants' coverage for secondary and tertiary hospitals were calculated separately.

[Please see supplementary files section to access the equation] (1)

Y_i : Coverage inhabitants in a given year;

P_i : Total population in a given year in province i ;

n_i : Number of sample hospitals in province i ;

N_i : Number of total hospitals in province i ;

m_i : Number of inpatients and outpatients in sample hospitals in province i ;

M^i : Number of inpatients and outpatients in all hospitals in province i .

In addition to ATC classification, we adopted 'Access, Watch, Reserve' (AWaRe) categorization established by WHO as part of the update of the WHO Model List of Essential Medicines in 2017 to analyse the antibiotic sales [16].

To derive a comparable metric of antibiotic sales across time, we calculated the compound annual growth rate (CAGR) of antibiotic sales [4].

[See supplementary files] (2)

C_{2018} : Total antibiotic sales for the year 2018 (expressed in DID).

C_{2011} : Total antibiotic sales for the year 2011 (expressed in DID).

All the relevant census data for calculating inhabitants were collected from China Health Statistics Yearbook and China Statistics Year Book [17]. Linear regression analysis was adopted to determine the trends in antibiotic use with time. A difference with $p < 0.05$ was considered to indicate statistical significance.

Results

Total antibiotic use in China's hospitals from 2011 to 2018

Between 2011 and 2018, total antibiotic sales in China's hospitals increased by 39.6% (from 4.8 DID in 2011 to 6.7 DID in 2018). The CAGR of the total antibiotic sales was 4.3%. In 2018, antibiotics in the Access category comprised 19.4% of total sales (1.3 DID/6.7 DID), whereas antibiotics in the Watch category represented the largest proportion of all – 71.6% (4.8 DID/6.7 DID). The percentage of antibiotics in the Access, Watch and Reserve categories was stable during the study period.

Cephalosporins were the most consumed antibiotics, accounting for 26.9% of the total antibiotic sales in 2018 (1.8 DID/6.7 DID), followed by combinations of penicillins with 22.4% (1.5 DID/ 6.7 DID) and fluoroquinolones with 10.4% (0.7 DID/6.7 DID). The largest absolute increase in sales between 2011 and 2018 was observed for combinations of penicillins (0.6 DID), cephalosporins (0.3 DID), and fluoroquinolones (0.2 DID). The most important relative increase from 2011 was observed for carbapenems (233.3%, from 0.03 DID to 0.1 DID), tetracyclines (200.0%, from 0.1 DID to 0.3 DID), other antibacterials (fosfomycin, daptomycin, spectinomycin, linezolid, methenamine) (50.0%, from 0.4 DID to 0.6 DID), combinations of penicillins (50.0%, from 1.0 DID to 1.5 DID) and penicillins with extended spectrum (50.0%, from 0.2 DID to 0.3 DID). (Figure 1, and Additional file 1).

Figure 1 Antibiotic sales under the WHO AWaRe category in China's hospitals, 2011-2018. (a) Expressed in DID. (b) Expressed in cumulative percentage.

Beijing, Jiangsu, and Shanghai were the top three largest consumers of antibiotics in 2018, with 18.3 DID, 16.7 DID, and 11.6 DID, respectively. Antibiotic sales were stable or had moderately decreased in half of the country (13 provinces), while in the other half (15 provinces) they had substantially increased between 2011 and 2018. Most of the increases in antibiotic sales were observed in underdeveloped regions, such as Inner Mongolia, Yunnan, Gansu, and Guizhou. Eastern coastal regions consumed more antibiotics compared with central and western regions (Figure 2).

Figure 2 Antibiotic sales in China's hospitals in 2018. (a) Expressed in DID; (b) Expressed in compound annual growth rates of antibiotic sales between 2011 and 2018.

Antibiotic sales in secondary and tertiary hospitals

In 2018, total antibiotic sales in secondary and tertiary hospitals were 7.3 DID and 6.6 DID, respectively. Antibiotics in the Access category comprised 27.4% (2.0 DID/7.3 DID) and 19.7% (1.3 DID/6.6 DID) of total sales in secondary and tertiary hospitals, respectively, whereas antibiotics in the Watch category had the largest proportion of 68.5% (5.0 DID/7.3 DID) and 72.7% (4.8 DID/ 6.6 DID), respectively. Antibiotics in the Reserve category in tertiary hospitals increased from 4.1% (0.3 DID/ 7.3 DID) to 7.6% (0.5 DID/ 6.6 DID) during the study period (Figure 3).

Figure 3 Antibiotic sales under WHO AWaRe category in secondary and tertiary hospitals, 2011-2018.

Antibiotic sales in secondary hospitals fell by 6.9% (7.3 DID to 6.8 DID) from 2011 to 2015 and rose by 7.4% (6.8 DID to 7.3 DID) from 2015 to 2018. In tertiary hospitals, antibiotic sales increased each year, and a 43.5% increase was observed between 2011 and 2018 (4.6 DID to 6.6 DID). The antibiotics sales of oral form were almost two times the sales of parenteral forms in secondary hospitals, whereas in tertiary hospitals the amounts were about the same. (Figure 4)

Figure 4 Oral and parenteral antibiotics consumed in secondary and tertiary hospitals between 2011 and 2018. (a) Oral antibiotic sales; (b) Parenteral antibiotic sales; (c) Total antibiotic sales

As Figure 5 showed, the three most commonly consumed antibiotics in secondary hospitals were second-generation cephalosporins, macrolides, and third-generation cephalosporins, whereas the combinations of penicillins, which increased by 63.5% from 0.96 DID to 1.57 DID between 2011 and 2018, replaced second-generation cephalosporins as one of the top three in tertiary hospitals in 2018 (Figure 3).

Figure 5 Major classes of antibiotics consumed in secondary and tertiary hospitals between 2011 and 2018. (a) Secondary hospitals; (b) Tertiary hospitals

Discussion

This study, to our knowledge, is the first to estimate population-wide antibiotic sales at the national level in China for an 8-year period, using data from a national sampling database and the accepted ATC/DDD methodology. This allows to analyse the antibiotic sales in China's hospital setting and benchmark it internationally, which would be informing for healthcare providers, decision-makers, as well as the public.

In the nearly past two decades, the Chinese government has attempted to confine AMR by a series of policies and measures including limiting antibiotic use. The evolution of the policy management has been well documented [10]. According to the National Health Commission, the outpatient antibiotic prescription proportion in Chinese hospitals (secondary and tertiary hospitals) has continuously declined from 16.2% in 2011 to 7.7% in 2017. Similarly, the inpatient antibiotic prescription proportion has also declined from 55.2% to 38.0% [18]. In addition, studies were conducted on the impact of antibiotic use in secondary and tertiary hospitals, analysing the effect of various drug management programs on promoting the proper use of antibiotics. It should be noted that the implementation of the zero mark-up policy cut off the economic incentives between the volume of prescriptions and the hospital revenue [14, 19, 20]. However, our study showed that antibiotic sales in China's hospitals increased significantly (38.2% increase between 2011 and 2018). Although the developed regions with larger populations consumed more antibiotics, significant increases were observed in underdeveloped regions despite having smaller populations (4 out of the top 5 provinces with the highest increase in antibiotic use were underdeveloped). While it can be hard to explain the discrepancy with other studies that describe a decrease in antibiotic use [21-24], we found evidence that is consistent with the increasing trend, when considering changes in the pharmaceutical market and inpatient volume. China's anti-infection pharmaceutical market continuously increased from 2011 to 2017 with varying growth rates. The inpatient volume at China's tertiary hospitals nearly tripled between 2010 to 2017

according to China Health Statistics Yearbook [17]. What's more, although the proportion of antibiotic prescriptions was decreasing, the median antibiotic usage intensity in 177 core members of China Antimicrobial Resistance Surveillance System was slightly increasing from 2014 to 2016 from 47.21 to 47.65 DDDs/100 patient days. In addition, the methodology in our study was different from the one used in the national report. The difference stems from the latter report extracting data from the Centre for Antibacterial Surveillance, which is a national surveillance network for collecting antibiotic prescription data across more than 1300 hospitals nationwide. This difference in methodology might be a potential explanation for the discrepancy.

When compared with European countries, our results showed that antibiotic sales in China's hospitals were more than three times than the average level (mean) of antibiotic sales in the hospital setting within 24 EU/EEA countries (2.0 DID in 2017, ranged from 0.9 to 3.1 DID) [25]. One more worrying fact was that the antibiotic sales in China's hospitals increased by a CAGR of 4.3% while the same metric, taken on an average annual basis in EU/EEA countries' hospital settings was 1.0% [25]. However, these results need to be interpreted with caution, because in EU/EEA countries outpatient antibiotic use accounted for 90%–94% of the total (considering countries that provided separate data in ESAC) [25, 26], whilst the majority of antibiotics were consumed in a hospital setting in China. This might explain why the sales of antibiotics in China's hospitals were lower than that of antibiotics consumed in the community setting in EU/EEA countries (6.3 DID vs 21.8 DID in 2017) [25]. AWaRe categories are proposed by WHO in the context of a comprehensive review of the optimal antibiotic choices for many common infectious syndromes in adults and children. WHO set up a global target of having the proportion of Access antibiotics be greater than 60% of all antibiotics prescribed to reduce AMR [27]. Our study showed that the Access category proportion in the sample hospitals was only 19.4%, which is lower than the proportion in most countries that collected this data [27]. The massive use of second- and third-generation cephalosporins, macrolides, as well as combinations of penicillins contributed to the high proportion of the Watch category. Measuring antibiotic sales by quantifying the use of antibiotics in each of the AWaRe categories allows some inference about the overall quality of antibiotic use between countries. The combination of both absolute and relative sales by category allows simple benchmarking (e.g. an overuse of Watch antibiotics can become immediately apparent and a reduction in Watch antibiotics can be identified as a target for antibiotic stewardship interventions) and assessment of trends over time (to evaluate the impact of interventions) [2].

When looking at the pattern of antibiotic sales, we found that cephalosporins were the most consumed antibiotics in China's hospitals, followed by combinations of penicillins, which were often defined as extended-spectrum antibiotics, and quinolones. This pattern was similar to the previous studies conducted in other regions of China [19, 20], as well as national surveillance data [18]. Unlike in China, more penicillins were prescribed in Europe and the United States [28-30]. This might partly be attributed to the different settings that antibiotics were consumed: mostly inpatient in China compared to an ambulatory setting in Europe and the US. Cephalosporins were recommended by the national guidance for the majority of the perioperative prophylaxis settings in China [31]. Although quinolones were recommended by US FDA to those who have no other treatment options [32], Chinese physicians may prefer quinolones and cephalosporins more than penicillins due to the time-consuming skin allergy testing requirements for penicillins prior to administration [33]. Although the sales of carbapenems, a class of last-resort antibiotics, were similar to EU/EEA countries (0.10 DID vs 0.06 DID in 2017, country range: 0.02-0.17), the significant increase of carbapenems sales still cannot be ignored (0.03 DID in 2011 to 0.10 DID in 2018) [25]. Because carbapenems are categorized as highly restricted antibiotics by the National Health Commission and require pre-authorization before use in China, this increase could be partly due to the rise in extended-spectrum β -lactamase-producing Gram-negative bacteria, which has been identified in epidemiological surveillance studies [18, 34]. Alongside the increase of carbapenem sales, the resistance rate of carbapenem-resistant Enterobacteriaceae has also been reported [35].

Population-weighted antibiotic sales were greater in secondary hospitals than in tertiary hospitals. As more severe patients were admitted in tertiary hospitals compared with secondary hospitals, we speculated that more potential inappropriate use of antibiotics might exist in lower level hospitals. Studies found that diseases, such as diarrheal illness, colds, pharyngitis, acute bronchitis, were likely to be prescribed antibiotics in rural and underdeveloped regions [36-38], although most of these illnesses are viral instead of bacterial. This is consistent with our results that most of the increases in antibiotic sales were observed in underdeveloped regions. This phenomenon may be severe in the primary healthcare setting, especially in rural areas, not only because regulations of antibiotic use have not been developed, but also the knowledge level of the physicians in the primary healthcare setting are lower than the physicians in the hospital setting [37]. However, further study on the level of individual antibiotic usage, such as a manual medical record review, is needed to confirm our speculation.

The findings of this study are subject to several limitations. First, the hospitals in the database were on a voluntary basis instead of mandatory participation, especially the proportion of secondary hospitals in the study was relatively low, therefore could bring selected bias. Second, primary healthcare setting was not included which may cause bias on the pattern of antibiotic sales since a number of antimicrobial agents was used in the primary care setting. Third, the population denominator used in the study was determined under certain conditions which may underestimate antibiotic sales as it cannot include cross-provincial patient flow. Besides, since we cannot access bed day data and the size of the hospital, the estimation of the population covered by the sample hospitals might be biased. Finally, as the study analysed sales data rather than clinical usage of antibiotics, we were unable to determine the appropriateness of antibiotic use at the individual level.

Conclusions

The study adopted aggregated sales data to analyse the antibiotic sales in China's hospitals over an 8-year period. The increase of antibiotic sales, especially the increase of last-resort antibiotics raises serious concern for public health. Although efforts have been made towards restricting antibiotic use in the past decade by the Chinese government, antibiotic sales demonstrated an upward trend during the study period. To better facilitate proper antibiotic use, more efforts are needed to explore the appropriateness of antibiotic use at the individual level. Besides, incorporate the primary healthcare setting into the national surveillance network should be stressed for better understanding the epidemiology of antibiotic use and AMR from a more comprehensive perspective.

List Of Abbreviations

DDD: Defined daily dose

DID: DDD per 1,000 inhabitants per day

AMR: Antimicrobial resistance

WHO: World Health Organization

NHFPC: National Health and Family Planning Commission

SAC: Special Antimicrobial Stewardship Campaign

CMEI: China Medicine Economic Information

ATC: Anatomical Therapeutic and Chemical

AwaRe: Access, Watch, Reserve

CAGR: Compound annual growth rate

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

Aggregated annual sales data used for analyses are provided as supporting information. The raw individual hospital level data used to generate these results cannot be shared publicly because of the associated legislation. Data can be made available by China Pharmacy Association (contact via tel 86 10 65660788 or fax 86 10 65661656) for researchers who meet the criteria for access to confidential data and subject to a data access fee.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported by the National Natural Science Foundation of China (Grant No. 81861138048 and No. 71774005) (<http://www.nsfc.gov.cn/>) and China Medical Board (Grant No. 17-270) (<https://chinamedicalboard.org/>). The funders had no role in study

design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors' contributions

Conceptualization, XDG and LWS; methodology, HW and YZ; validation, XDG; formal analysis, HW, YZ, XZ and MYF; resources, XDG, LWS and DMF; data curation, YZ, XZ and MYF; writing—original draft preparation, HW and YZ; writing—review and editing, XDG; supervision, LWS and DMF; project administration, HW, YZ, and XZ; funding acquisition, XDG, LWS and DMF. All authors read and approved the final manuscript.

Acknowledgements

We thank the staff of the Scientific Development Center of China Pharmacy Association for their support and cooperation in data access and analysis.

References

1. Angebault C, Andremont A. Antimicrobial agent exposure and the emergence and spread of resistant microorganisms: issues associated with study design. *Eur J Clin Microbiol Infect Dis*. 2013 May;32(5):581–95.
2. OECD. Stemming the Superbug Tide: Just A Few Dollars More, OECD Health Policy Studies. Paris; 2018. <https://www.oecd-ilibrary.org/content/publication/9789264307599-en>. Accessed 21 Sep 2019.
3. Smith RD, Coast J. Antimicrobial resistance: a global response. *Bulletin of the World Health Organization*. 2002;8.
4. van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. *The Lancet Infectious Diseases*. 2014 Aug;14(8):742–50.
5. National Guiding Principles for Antimicrobial. 2019. http://www.gov.cn/xinwen/2015-08/27/content_2920799.htm. Accessed 21 Sep 2019.
6. Ministry of Health of China. National Guiding Principles for Antimicrobial. <http://www.sda.gov.cn/WS01/CL0055/10126.html>. Accessed 21 Sep 2019.
7. Ministry of Health of China. Notification on establishing surveillance network for antibiotic use and antimicrobial resistance. <http://www.nhfpc.gov.cn/zwgkzt/wsbyjsj/200804/18487.shtml>. Accessed 21 Sep 2019.
8. Ministry of Health of China. Notification on releasing clinical guidance of national essential medicine and national essential medicine formulary. <http://www.nhfpc.gov.cn/zwgkzt/wsbyjsj/201005/47420.shtml>. Accessed 21 Sep 2019.
9. Ministry of Health of China. National special rectification activities program of clinical use of antibiotics (2011). <http://www.moh.gov.cn/mohyzs/s3586/201104/51376.shtml>. Accessed 21 Sep 2019.
10. Xiao Y, Li L. Legislation of clinical antibiotic use in China. *The Lancet Infectious Diseases*. 2013 Mar;13(3):189–91.
11. National Health Commission of People's Republic of China. Notification on releasing National Action Plan on confining AMR (2016–2020). <http://www.nhfpc.gov.cn/yzygj/s3593/201608/f1ed26a0c8774e1c8fc89dd481ec84d7.shtml>. Accessed 21 Sep 2019.
12. Notification on releasing 3 technical documents of experts options on carbapenem antibiotics. <http://www.nhfpc.gov.cn/yzygj/s7659/201809/95f65ca473b44746b24590e94468b8ff.shtml>. Accessed 21 Sep 2019.
13. Bao L, Peng R, Wang Y, Ma R, Ren X, Meng W, et al. Significant Reduction of Antibiotic Consumption and Patients' Costs after an Action Plan in China, 2010–2014. *Singer AC, editor. PLoS ONE*. 2015 Mar 13;10(3):e0118868.
14. Wushouer H, Tian Y, Guan X-D, Han S, Shi L-W. Trends and patterns of antibiotic consumption in China's tertiary hospitals: Based on a 5 year surveillance with sales records, 2011–2015. *Zhou Z, editor. PLoS ONE*. 2017 Dec 27;12(12):e0190314.
15. World Health Organization. Anatomical Therapeutic Chemical (ATC) Classification System: Guidelines for ATC Classification and DDD Assignment. http://www.whocc.no/atc_ddd_index/. Accessed 21 Sep 2019.
16. World Health Organization. WHO Model List of Essential Medicines (20th list). 2017. https://www.who.int/medicines/publications/essentialmedicines/20th_EML2017.pdf?%20ua=. Accessed 21 Sep 2019.
17. National Bureau of Statistics. China Statistical Yearbook. <http://www.stats.gov.cn/english/Statisticaldata/AnnualData/>. Accessed 21 Sep 2019.
18. National Health Commission of People's Republic of China. Status report on antimicrobial administration and antimicrobial resistance in China (2018). 1st ed. Beijing: Peking Union Medical College Press; 2018.

<http://www.nhc.gov.cn/yzygj/s3594/201904/1b5a42f0e326487295b260c813da9b0e/files/65d864a34e824d1abbc6807cd3c999b1.pdf>. Accessed 21 Sep 2019.

19. Lin H, Dyar OJ, Rosales-Klintz S, Zhang J, Tomson G, Hao M, et al. Trends and patterns of antibiotic consumption in Shanghai municipality, China: a 6 year surveillance with sales records, 2009–14. *J Antimicrob Chemother*. 2016 Jun;71(6):1723–9.
20. Yin J, Li Q, Sun Q. Antibiotic consumption in Shandong Province, China: an analysis of provincial pharmaceutical centralized bidding procurement data at public healthcare institutions, 2012–16. *Journal of Antimicrobial Chemotherapy*. 2018 Mar 1;73(3):814–20.
21. Bhangu A, Ademuyiwa AO, Aguilera ML, Alexander P, Al-Saqqa SW, Borda-Luque G, et al. Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study. *The Lancet Infectious Diseases*. 2018 May;18(5):516–25.
22. Qu X, Yin C, Sun X, Huang S, Li C, Dong P, et al. Consumption of antibiotics in Chinese public general tertiary hospitals (2011–2014): Trends, pattern changes and regional differences. De Socio GV, editor. *PLoS ONE*. 2018 May 3;13(5):e0196668.
23. Li H, Yan S, Li D, Gong Y, Lu Z, Yin X. Trends and patterns of outpatient and inpatient antibiotic use in China's hospitals: data from the Center for Antibacterial Surveillance, 2012–16. *Journal of Antimicrobial Chemotherapy*. 2019 Jun 1;74(6):1731–40.
24. Chen J, Min R, Wang H, Zhao S, Li H, Fang P. Trends and Drivers of Inpatient Antibiotic Consumption among 89 China Tertiary General Hospitals from 2011Q1 to 2015Q4. *BioMed Research International*. 2018 Nov 1;2018:1–7.
25. European Centre for Disease Prevention and Control. Antimicrobial consumption. In: ECDC. Annual epidemiological report for 2017. https://ecdc.europa.eu/sites/portal/files/documents/AER_for_2017-antimicrobial-consumption.pdf. Accessed 21 Sep 2019.
26. Goossens H, Ferech M, Stichele RV, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. 2005;365:9.
27. World Health Organization. WHO Report on Surveillance of Antibiotic Consumption, 2016–2018 Early implementation. https://www.who.int/medicines/areas/rational_use/who-amr-amc-report-20181109.pdf. Accessed 21 Sep 2019.
28. van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, et al. Antimicrobial Drug Use and Resistance in Europe. *Emerg Infect Dis*. 2008 Nov;14(11):1722–30.
29. Public Health England. English surveillance programme for antimicrobial utilization and resistance (ESPAUR) Report 2016. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/575626/ESPAUR_Report_2016.pdf. Accessed 21 Sep 2019.
30. Durkin MJ, Jafarzadeh SR, Hsueh K, Sallah YH, Munshi KD, Henderson RR, et al. Outpatient Antibiotic Prescription Trends in the United States: A National Cohort Study. *Infect Control Hosp Epidemiol*. 2018 May;39(5):584–9.
31. Department of Medical Administration and Committee of Experts on Rational Drug Use, National Health, and Family Planning Commission of the People's Republic of China. National Antimicrobial Therapy Guidance. 1st ed. Beijing: People's Medical Publishing House Co Ltd; 2012. <https://huixue.baidu.com/book/detail?nid=e219cbc708a1284ac85043cb&isFromWenku=true>. Accessed 21 Sep 2019.
32. McCarthy M. US warns against use of fluoroquinolones for uncomplicated infections. *BMJ*. 2016 May 16;i2755.
33. National Health and Family Planning Commission of the People's Republic of China. Notification on Implementation of Guidelines for Clinical Application of Antimicrobial Agents. [http:// www.moh.gov.cn/wsb/pzcjd/200804/21154.shtml](http://www.moh.gov.cn/wsb/pzcjd/200804/21154.shtml). Accessed 21 Sep 2019.
34. Quan J, Zhao D, Liu L, Chen Y, Zhou J, Jiang Y, et al. High prevalence of ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* in community-onset bloodstream infections in China. *J Antimicrob Chemother*. 2017 Jan;72(1):273–80.
35. Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu B, et al. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network. *Antimicrob Agents Chemother*. 2017 Dec 4;62(2):e01882-17.
36. Guan X, Tian Y, Song J, Zhu D, Shi L. Effect of physicians' knowledge on antibiotics rational use in China's county hospitals. *Social Science & Medicine*. 2019 Mar;224:149–55.
37. Zhang Z, Hu Y, Zou G, Lin M, Zeng J, Deng S, et al. Antibiotic prescribing for upper respiratory infections among children in rural China: a cross-sectional study of outpatient prescriptions. *Global Health Action*. 2017 Jan;10(1):1287334.
38. Hou F-Q, Wang Y, Li J, Wang G-Q, Liu Y. Management of acute diarrhea in adults in China: a cross-sectional survey. *BMC Public Health*. 2013 Dec;13(1):41.

Supplementary Information

Additional file 1. S1 Table Antibiotic consumption in China's hospitals between 2011 and 2018.

Figures

Figure 1

Antibiotic sales under the WHO AWaRe category in China's hospitals, 2011-2018. (a) Expressed in DID. (b) Expressed in cumulative percentage.

Figure 2

Antibiotic sales in China's hospitals in 2018. (a) Expressed in DID; (b) Expressed in compound annual growth rates of antibiotic sales between 2011 and 2018. Note: The designations employed and the presentation of the material on this map do not imply the expression of any opinion whatsoever on the part of Research Square concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. This map has been provided by the authors.

Figure 3

Antibiotic sales under WHO AWaRe category in secondary and tertiary hospitals, 2011-2018.

Figure 4

Oral and parenteral antibiotics consumed in secondary and tertiary hospitals between 2011 and 2018. (a) Oral antibiotic sales; (b) Parenteral antibiotic sales; (c) Total antibiotic sales

Figure 5

Major classes of antibiotics consumed in secondary and tertiary hospitals between 2011 and 2018. (a) Secondary hospitals; (b) Tertiary hospitals

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile1.docx](#)
- [Equations.docx](#)